Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Down 24.2% in December

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) was the recipient of a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 3,540,000 shares, a decline of 24.2% from the November 30th total of 4,670,000 shares. Approximately 2.8% of the company's shares are sold short. Based on an average daily trading volume, of 1,060,000 shares, the short-interest ratio is presently 3.3 days.

Insider Activity

In other news, SVP Jason B. Daly sold 43,657 shares of Amneal Pharmaceuticals stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $8.61, for a total transaction of $375,886.77. Following the sale, the senior vice president now owns 13,665 shares of the company's stock, valued at approximately $117,655.65. The trade was a 76.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 26.56% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AMRX. Barclays PLC grew its position in shares of Amneal Pharmaceuticals by 134.1% during the 3rd quarter. Barclays PLC now owns 296,384 shares of the company's stock valued at $2,466,000 after acquiring an additional 169,756 shares during the period. State Street Corp grew its holdings in Amneal Pharmaceuticals by 3.8% during the third quarter. State Street Corp now owns 3,514,721 shares of the company's stock valued at $29,242,000 after purchasing an additional 127,753 shares during the period. Bank of New York Mellon Corp increased its position in Amneal Pharmaceuticals by 20.7% in the second quarter. Bank of New York Mellon Corp now owns 751,403 shares of the company's stock worth $4,771,000 after buying an additional 128,772 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of Amneal Pharmaceuticals by 701.8% in the second quarter. Acadian Asset Management LLC now owns 811,853 shares of the company's stock worth $5,148,000 after buying an additional 710,598 shares during the period. Finally, Jackson Creek Investment Advisors LLC purchased a new position in shares of Amneal Pharmaceuticals during the 2nd quarter valued at about $1,027,000. 31.82% of the stock is owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ AMRX traded down $0.03 during midday trading on Friday, hitting $7.82. 933,555 shares of the stock traded hands, compared to its average volume of 1,369,695. The firm has a market capitalization of $2.42 billion, a P/E ratio of -11.50 and a beta of 1.12. Amneal Pharmaceuticals has a one year low of $5.01 and a one year high of $9.48. The firm has a 50-day moving average of $8.34 and a two-hundred day moving average of $7.97.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on AMRX. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from an "underweight" rating to a "neutral" rating and set a $9.00 price objective on the stock in a research report on Friday, September 6th. Piper Sandler lifted their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an "overweight" rating in a research report on Monday, November 11th. Truist Financial increased their price objective on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Wednesday, October 2nd. Finally, StockNews.com cut shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, December 19th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $10.00.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.